Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation.

Authors

Lori S. Muffly

Stanford University, Stanford, CA

Lori S. Muffly , Michelle Chin , Hye-Sook Kwon , Cara Lieber , Steven Smith , Robert Sikorski , Judith Shizuru , Wendy Pang , Andrew S. Artz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Non-myeloablative allogeneic blood or marrow transplantation (AlloBMT) with post-transplant cyclophosphamide (PTCy) for peripheral T-cell lymphoma (PTCL): Improved outcomes with peripheral blood (PB) allografts and increased total body irradiation (TBI) to 400 cGV.

First Author: Cole Harris Sterling

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Post-transplant lymphoproliferative disorder in kidney transplant patients: A multicenter report.

First Author: Elise A. Chong

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Incidence of large granular lymphocytosis (LGL) in patients with late cytopenias after allogeneic blood or marrow transplantation (AlloBMT).

First Author: Marcus Messmer

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) in older patients using fludarabine and total body irradiation (Flu/TBI).

First Author: Omer Hassan JAMY